SynAct Pharma AB (OSTO:SYNACT) Other Current Liabilities: kr10.38 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
18 GF Score
Price kr21.80
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB Other Current Liabilities?

SynAct Pharma AB OSTO:SYNACT +2.11% 18 Other Current Liabilities is kr10.38 Mil as of Mar. 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

SynAct Pharma AB's other current liabilities for the quarter that ended in Mar. 2026 was kr10.38 Mil.

SynAct Pharma AB's quarterly other current liabilities declined from Sep. 2025 (kr21.40 Mil) to Dec. 2025 (kr13.99 Mil) and declined from Dec. 2025 (kr13.99 Mil) to Mar. 2026 (kr10.38 Mil).

SynAct Pharma AB's annual other current liabilities declined from Dec. 2023 (kr12.57 Mil) to Dec. 2024 (kr10.85 Mil) but then increased from Dec. 2024 (kr10.85 Mil) to Dec. 2025 (kr13.99 Mil).

SynAct Pharma AB Other Current Liabilities Related Terms

SynAct Pharma AB Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB Other Current Liabilities Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.40 5.60 12.57 10.85 13.99

SynAct Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.05 13.93 21.40 13.99 10.38
OSTO:SYNACT
18GF Score
SynAct Pharma AB OSTO:SYNACT
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of kr10.38 Mil mean?
SynAct Pharma AB (OSTO:SYNACT) has a Other Current Liabilities of kr10.38 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on SynAct Pharma AB.
Is SynAct Pharma AB's Other Current Liabilities too high?
SynAct Pharma AB's current Other Current Liabilities is kr10.38 Mil. Overall, SynAct Pharma AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's Other Current Liabilities compare to VRTX and REGN?
SynAct Pharma AB's Other Current Liabilities of kr10.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on SynAct Pharma AB. SynAct Pharma AB's current Other Current Liabilities is kr10.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current Other Current Liabilities of kr10.38 Mil. The current Other Current Liabilities is kr10.38 Mil. SynAct Pharma AB's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current Other Current Liabilities is kr10.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
18GF Score

Get the complete analysis for OSTO:SYNACT

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr21.80
Price